Transplanting Against Histocompatibility Barriers

D. Kannabhiran,M. Lubetzky,D. Dadhania

DOI: https://doi.org/10.5772/54346

2012-12-19

Abstract:Currently there are over 90,000 patients awaiting a kidney transplant in the United States. Despite the large number of wait-listed patients, just over 16,000 were transplanted in 2009 [1]. Mean waiting times for transplantation can range from 2 years to over 5 years depending on a variety of factors including blood type, sensitization status and deceased donor availability in the region. Despite the availability of a willing living donor, a patient may be forced to remain on the deceased donor waiting list because of ABO incompatibility (ABOi) and/or the presence of a positive crossmatch due to donor specific anti-HLA antibodies. Those with blood O and B tend to have the longest wait times (median waiting time for O:1852 days; A:1208 days; B:1937 days; AB: 855 days) and may also have difficulty finding a compatible living donor [2]. Sensitized patients are those with high levels of antiHLA (Human Leukocyte Antigen) antibodies in their blood. These antibodies form as a result of exposure to foreign HLA during pregnancy, transfusions and exposure to previous organ transplants. Approximately 16% of patients on the waiting list are re-transplants. Patients who are sensitized (Panel Reactive Antibody, PRA 10% or greater) make up roughly 25% of the current waiting list, 16% of which have a PRA >80% [1]. In some cases, a highly sensitized patient can wait up to 10 years before being transplanted. These wait times a negative impact on patients as the morbidity and mortality of dialysis patients are higher compared to kidney transplant recipients[3]. In 2010 over 5,000 patients died while waiting to receive a kidney transplant [1]. Given the increased mortality associated with dialysis, renal transplantation remains the preferred treatment for patients with end stage renal disease [4].